Floatz logo

Vindesine

B-Cell Non-Hodgkin Lymphoma

Children's Cancer Group, ChinaSmall moleculePhase 4 / ApprovedActive
BBB
78/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
70/ 100
Competitive Position
89/ 100

Competitive context

305 Active assets in the B-Cell Non-Hodgkin Lymphoma cohort.

Asset / SponsorPhaseRating
ANTI-CD20/CD3 MONOCLONAL ANTIBODY REGN1979
University of Birmingham
Phase 3BBB
Cytarabine
Children's Cancer Group, China
Phase 4BBB
METHOTREXATE
Children's Cancer Group, China
Phase 4BBB
Zanubrutinib
The First Affiliated Hospital of Soochow University
Phase 4BBB
ISOCYCLOPHOSPHAMIDE
Shanghai Junshi Bioscience Co., Ltd.
Phase 4BBB

View all 50 →

Same molecule, other indications

Vindesine is also rated in:

adult acute lymphoblastic leukemiaActive
BBB
Indicative · Phase 4
78 / 100
View asset →
Burkitt lymphomaDormant
BBB
Indicative · Phase 4
75 / 100
View asset →
lymphoblastic lymphomaActive
BBB
Indicative · Phase 4
72 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →